**Title:** A novel antibody that targets TNFR2, a key regulator of the tumor immunosuppressive microenvironment


**Affiliation:** Merrimack Pharmaceuticals, Inc., Cambridge MA, USA

**Abstract:** ENA-0373

**Graphs and Figures:**
- **Graph 1:** Scatterplot showing the relationship between Tumor Volume and Percent Survival.
- **Graph 2:** Bar chart depicting the percentage of different immune cell populations.
- **Graph 3:** Line graph illustrating the changes in Tumor Volume over time.

**Additional Information:**
- **x** \( Y \) axis: Percent survival, Tumor Volume (mm³)
- **y** \( Y \) axis: Days post inoculation

**Tables:**

<table>
<thead>
<tr>
<th>Tumor Volume (mm³)</th>
<th>Days post inoculation</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>500</td>
<td>5</td>
</tr>
<tr>
<td>1000</td>
<td>10</td>
</tr>
<tr>
<td>1500</td>
<td>15</td>
</tr>
<tr>
<td>2000</td>
<td>20</td>
</tr>
</tbody>
</table>

**References:**

- **Figure 1:** Scatterplot showing the relationship between Tumor Volume and Percent Survival.
- **Figure 2:** Bar chart depicting the percentage of different immune cell populations.
- **Figure 3:** Line graph illustrating the changes in Tumor Volume over time.

**Conclusion:**

ENA-0373 is a novel antibody that targets TNFR2, a key regulator of the tumor immunosuppressive microenvironment. The antibody showed significant efficacy in preclinical models, leading to the development of clinical trials for various tumor types.